JPMorgan initiated coverage of ANI Pharmaceuticals (ANIP) with an Overweight rating and $85 price target ANI is a specialty pharmaceuticals ...

Jefferies initiated coverage of ANI Pharmaceuticals (ANIP) with a Buy rating and $80 price target The firm expects continued momentum for the ...

StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) from a sell rating to a hold rating in a ...

ANI Pharmaceuticals (ANIP) stock was granted an Overweight rating by J.P. Morgan on Wednesday based on the company's growth ...

Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy ...

Fintel reports that on March 14, 2025, Jefferies initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a Buy ...

J.P. Morgan on Wednesday launched its coverage of ANI Pharmaceuticals (NASDAQ:ANIP) with an Overweight recommendation and a year-end price target of $85 per share, citing the specialty pharma ...

Fintel reports that on March 12, 2025, JP Morgan initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a Overweight ...

PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified ...

The stock market is facing a sharp correction after two years of gains. Major U.S. indexes have entered correction territory, with technology and semiconductor stocks leading the decline. Investor ...